The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
04
2020
accepted:
20
06
2020
entrez:
30
7
2020
pubmed:
30
7
2020
medline:
12
9
2020
Statut:
epublish
Résumé
New hepatitis C virus (HCV) treatments spurred the World Health Organization (WHO) in 2016 to adopt a strategy to eliminate HCV as a public health threat by 2030. To achieve this, key policies must be implemented. In the absence of monitoring mechanisms, this study aims to assess the extent of policy implementation from the perspective of liver patient groups. Thirty liver patient organisations, each representing a country, were surveyed in October 2018 to assess implementation of HCV policies in practice. Respondents received two sets of questions based on: 1) WHO recommendations; and 2) validated data sources verifying an existing policy in their country. Academic experts selected key variables from each set for inclusion into policy scores. The similarity scores were calculated for each set with a multiple joint correspondence analysis. Proxy reference countries were included as the baseline to contextualize results. We extracted scores for each country and standardized them from 0 to 10 (best). Twenty-five countries responded. For the score based on WHO recommendations, Bulgaria had the lowest score whereas five countries (Cyprus, Netherlands, Portugal, Slovenia, and Sweden) had the highest scores. For the verified policy score, a two-dimensional solution was identified; first dimension scores pertained to whether verified policies were in place and second dimension scores pertained to the proportion of verified policies in-place that were implemented. Spain, UK, and Sweden had high scores for both dimensions. Patient groups reported that the European region is not on track to meet WHO 2030 HCV goals. More action should be taken to implement and monitor HCV policies.
Sections du résumé
BACKGROUND
New hepatitis C virus (HCV) treatments spurred the World Health Organization (WHO) in 2016 to adopt a strategy to eliminate HCV as a public health threat by 2030. To achieve this, key policies must be implemented. In the absence of monitoring mechanisms, this study aims to assess the extent of policy implementation from the perspective of liver patient groups.
METHODS
Thirty liver patient organisations, each representing a country, were surveyed in October 2018 to assess implementation of HCV policies in practice. Respondents received two sets of questions based on: 1) WHO recommendations; and 2) validated data sources verifying an existing policy in their country. Academic experts selected key variables from each set for inclusion into policy scores. The similarity scores were calculated for each set with a multiple joint correspondence analysis. Proxy reference countries were included as the baseline to contextualize results. We extracted scores for each country and standardized them from 0 to 10 (best).
RESULTS
Twenty-five countries responded. For the score based on WHO recommendations, Bulgaria had the lowest score whereas five countries (Cyprus, Netherlands, Portugal, Slovenia, and Sweden) had the highest scores. For the verified policy score, a two-dimensional solution was identified; first dimension scores pertained to whether verified policies were in place and second dimension scores pertained to the proportion of verified policies in-place that were implemented. Spain, UK, and Sweden had high scores for both dimensions.
CONCLUSIONS
Patient groups reported that the European region is not on track to meet WHO 2030 HCV goals. More action should be taken to implement and monitor HCV policies.
Identifiants
pubmed: 32722701
doi: 10.1371/journal.pone.0235715
pii: PONE-D-20-09886
pmc: PMC7386634
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0235715Subventions
Organisme : Department of Health
ID : 14/02/17
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P025064/1
Pays : United Kingdom
Organisme : Department of Health
ID : RP-2016-07-012
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have read the journal's policies and declare the following competing interests: This study was directly funded by ELPA, who in turn were funded by AbbVie, Gilead Sciences, and Merck & Co. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Lancet Glob Health. 2013 Sep;1(3):e127-8
pubmed: 25104254
J Clin Epidemiol. 2010 Jun;63(6):638-46
pubmed: 19896800
Infect Agent Cancer. 2016 Oct 12;11:53
pubmed: 27752280
Epidemiol Infect. 2017 Oct;145(14):2873-2885
pubmed: 28891457
BMC Infect Dis. 2014;14 Suppl 6:S18
pubmed: 25252919
J Hepatol. 2017 Oct;67(4):665-666
pubmed: 28760329
J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25052
pubmed: 29633562
Ecol Indic. 2017 Sep;80:12-22
pubmed: 28867964
AIDS Behav. 2017 Jul;21(Suppl 1):44-50
pubmed: 27734168
J Hepatol. 2018 Nov;69(5):1188-1196
pubmed: 29959953
Int J Drug Policy. 2017 Sep;47:47-50
pubmed: 28689856
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
AIDS Behav. 2017 Jul;21(Suppl 1):51-61
pubmed: 28084561
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):125-133
pubmed: 28986139
Harm Reduct J. 2018 May 11;15(1):25
pubmed: 29751763
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
Semin Liver Dis. 2018 Aug;38(3):181-192
pubmed: 29986353